ConductScience.org, home

Comparison · NCT01840072-02ba9cba

Active Antihypertensive Treatment vs Usual Care: Recurrent Stroke

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Active Antihypertensive Treatment vs Usual Care: Recurrent Stroke. Trial comparisons, record NCT01840072-02ba9cba. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01840072-02ba9cba

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01410.009760.0203wilson
Risk in group 20.02160.01610.029wilson
Risk difference, group 1 minus group 2-0.00756-0.01610.000752newcombe hybrid score
Risk ratio, group 1 over group 20.6510.4061.04log
Odds ratio, group 1 over group 20.6460.41.04log
Number needed to treat, for one fewer participant with the outcome on Active Antihypertensive Treatment than on Usual Care132from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: usual care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Active Antihypertensive Treatment
Active antihypertensive treatment~Active antihypertensive treatment: Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
281,988OG000
Group 2Usual CareDiscontinue all home BP medications.431,987OG001

Outcome

Type
SECONDARY
Title
Recurrent Stroke
Description
Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected.
Time frame
3 months
Population

Source ClinicalTrials.gov

Trial

Title
China Antihypertensive Trial in Acute Ischemic Stroke
NCT number
NCT01840072
Phases
NA
Conditions
Ischemic Stroke
Interventions
Active antihypertensive treatment
Lead sponsor
Tulane University
Results first posted
2014-11-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01840072-02ba9cba